In this episode, Dr. Jaime Almandoz, Associate Professor of Medicine at UT Southwestern, is joined by Dr. Robert F. Kushner, Professor of Medicine at Northwestern University and a leading authority in obesity medicine, to discuss the recent Lancet Diabetes & Endocrinology Commission report, “Definition and Diagnostic Criteria of Clinical Obesity.” The report introduces a new framework for defining clinical and preclinical obesity, aiming to move beyond the limitations of BMI. Dr. Kushner shares insights into the Commission’s global consensus process and how the updated definitions can transform care, reduce weight stigma, and support more targeted treatment. Don’t miss this timely conversation on the evolving future of obesity diagnosis and management.

Join 2025 Annual Meeting Chair, Cecilia Low Wang, MD, FACP, FACE, as she interviews Rachna Relwani, MD, Chair of the Environmental Endocrinology Topic Interest Group (TIG), and David C. Lieb, MD, FACP, FACE, Chair of the Artificial Intelligence and Clinical Endocrinology TIG. In this episode, you'll gain insight into how these TIGs are advancing critical conversations, fostering collaboration through AACE’s new Facebook Groups, and preparing for engaging meetups at the AACE Annual Meeting in Orlando, May 15–17. Whether you're passionate about environmental health or curious about the role of AI in clinical practice, this episode offers a dynamic preview of what’s ahead.

Join endocrine experts Lubaina S. Presswala, DO, FACOI, FACE; Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, FADCES; and Viral N. Shah, MD, FACE, as they explore the latest in continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems for managing diabetes. In this episode, they discuss the practical applications of diabetes technology, patient selection, shared decision-making, and considerations for device use in specific populations, including athletes and pregnant individuals. This conversation provides valuable insights to help clinicians navigate device options and enhance outcomes across diverse patient scenarios.

Join Dr. David Lieb as he moderates a discussion with Dr. Jaydira Del Rivero, Chair of the MEN1 Consensus Statement Task Force, and Dr. Michelle Lundholm, Methodology Fellow, about the recently released 2025 AACE Consensus Statement on the Management of Multiple Endocrine Neoplasia, Type 1 (MEN1).

This episode covers:

1. AACE’s updated consensus statement methodology, including the new methodology fellow and patient representative roles
2. The role of surgical and non-surgical management strategies for patients with different types of MEN1-related tumors
3. The importance of patient values and preferences and risks/benefits of different screening modalities when determining appropriate screening frequencies for patients
4. Current gaps in the literature and future considerations for MEN1 research

Early detection and monitoring of Type 1 Diabetes (T1D) are crucial for improving patient outcomes and quality of life. Join clinical experts Lubaina S. Presswala, DO, FACOI, FACE; Jeff Unger, MD, FAAFP, FACE, DACD; and Javier Morales, MD, FACP, FACE, as they discuss the growing prevalence of T1D, the importance of autoantibody screening, the different stages of T1D, screening guidelines, patient counseling, and how early intervention can help delay progression and reduce complications. Support for this podcast is provided by Sanofi.

In this episode, join moderator Dr. David Lieb alongside esteemed panelists Dr. Shahnaz Sultan, Dr. Carol Peng, and Dr. Melanie Bird as they delve into the methodology behind the 2025 AACE Clinical Practice Guideline on Pharmacologic Management of Adults with Dyslipidemia.

Discover insights into:

• Why AACE adopted the GRADE framework and its implications for guideline development.
• The critical role of systematic reviews in creating evidence-based recommendations.
• How evidence is assessed using the GRADE approach.
• Practical takeaways for clinicians when implementing GRADE-informed guidelines in patient care.

Whether you’re a seasoned practitioner or new to the field, this discussion offers valuable perspectives on the evolution of evidence-based guideline development and its impact on clinical practice.

Join Dr. David Lieb as he moderates an engaging discussion with Dr. Shailendra Patel, Chair of the Dyslipidemia Guideline Task Force, and Dr. Kathleen Wyne, Vice Chair, about the recently released 2025 AACE Clinical Practice Guideline on Pharmacologic Management of Adults with Dyslipidemia.

This episode covers:

• What’s new or different in this update compared to the 2017 guideline.
• Surprising insights revealed during the evidence assessments and how they shaped the recommendations.
• Key considerations for clinicians as they integrate these updated recommendations into practice.
• Gaps in the literature and opportunities for future research.

Whether you’re familiar with the previous guideline or new to this topic, this conversation provides a comprehensive overview of the latest advancements in dyslipidemia management.

Join endocrine expert Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU, for a special AACE Podcast featuring her patient, Andree. Together, they explore Andree’s personal journey with thyroid disease and how the AACE Journey for Patients With Thyroid Disease website has been an invaluable resource, offering clear and accessible tools to navigate her thyroid condition with confidence. Don’t miss this inspiring discussion, brought to you with the support of AbbVie and Amgen Rare Disease.

Join endocrine experts Vin Tangpricha, MD, PhD, FACE, Editor-in-Chief of Endocrine Practice (EP) and Professor of Medicine at Emory University School of Medicine, and Rifka C. Schulman-Rosenbaum, MD, FACE, FACP, Director of Inpatient Diabetes at Long Island Jewish Medical Center, Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Northwell Health, and Chair Elect for the AACE 2025 Annual Meeting, as they discuss Dr. Schulman-Rosenbaum’s EP article, “Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia.” Tune in as they explore the complexities of managing inpatient hyperglycemia, the risks of SGLT-2 inhibitors in hospitalized patients, and who might be good candidates for safer alternatives like DPP-4 inhibitors and insulin. Packed with valuable insights and practical strategies, this discussion is essential for optimizing hospital-based diabetes care. Read the full article in the April 2024 issue of EP here.

Join endocrine experts Vin Tangpricha, MD, PhD, FACE, Editor-in-Chief of Endocrine Practice (EP) and Professor of Medicine at Emory University School of Medicine, and Cecilia C. Low Wang, MD, FACE, FACP, Professor of Medicine and Medical Director for the Glucose Management Team at the University of Colorado, as they discuss Dr. Low Wang's impactful EP article titled "Safety and Efficacy of Insulins in Critically Ill Patients Receiving Continuous Enteral Nutrition." Tune in as they explore strategies for managing hyperglycemia and hypoglycemia in hospitalized patients on continuous tube feeds, evaluate insulin regimens such as 70/30 Q-8 hours and basal-bolus, examine differences in glycemia management for patients with and without diabetes, and discuss ways to optimize glycemic control. View the full article in the April 2024 issue of EP here.